Why the study?
Patients with type 2 diabetes post-MI face elevated recurrent cardiovascular risk despite optimal therapy, prompting evaluation of low-dose colchicine for secondary prevention.
Does low-dose colchicine reduce major adverse cardiovascular events in post-myocardial infarction patients, particularly those with type 2 diabetes?
Population
Approximately 12,000 participants across 14 RCTs of post-MI patients including type 2 diabetes subgroups
Comparison
Low-dose colchicine (0.5 mg/day) vs comparator
Design
Systematic review of 14 randomized controlled trials
Authors
Loading...
Supports low-dose colchicine for secondary prevention in diabetic patients post-MI; extends prior.
Does low-dose colchicine reduce major adverse cardiovascular events in post-myocardial infarction patients, particularly those with type 2 diabetes?
Low-dose colchicine provides substantial cardiovascular protection and cost-effectiveness for secondary prevention in post-MI patients, particularly those with type 2 diabetes, despite a slightly elevated risk of pneumonia.
Shoaib et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: